Diagnostic Value of GATA3 and Uroplakin 3 in Differentiating Urothelial Carcinoma from Prostatic and Colorectal Carcinoma
DOI:
https://doi.org/10.3889/oamjms.2022.8282Keywords:
GATA3, Uroplakin 3, Urothelial, Prostate, Colorectal, CarcinomaAbstract
BACKGROUND: Prostate involvement by urothelial carcinoma (UC) can occur from direct invasion. Involvement of the urinary bladder by prostate adenocarcinoma (PAC) may similarly occur, representing a common diagnostic problem especially in high-grade tumors. Furthermore, colorectal carcinoma (CRC) invades the urinary bladder which represents another challenging task for the pathologists, a problem not only in the urinary bladder but also in lymph node metastasis. Uroplakin 3 has been used for differentiation but unfortunately, its sensitivity is not so high especially in high-grade cases. Recently, GATA3 was recognized as being involved in development of urothelium.
AIM: Few studies elaborated its expression in high-grade UC; therefore, this study aimed at evaluating GATA3 and comparing it to uroplakin 3 expression in differentiating the three tumors from each other.
MATERIALS AND METHODS: Sixty paraffin blocks collected and distributed as 20 cases of invasive UC, 20 cases of PAC, and 20 cases of CRC, all high grade, to be studied immunohistochemically against GATA3 and uroplakin 3.
RESULTS: GATA3 expression was positive in 80% of UC compared to none of the cases of PAC or CRC. The sensitivity of GATA3 in diagnosing UC was 80% whereas the specificity was 100%. Uroplakin 3 was positive in 50% of UC compared to none of the cases of PAC or CRC. The sensitivity of uroplakin 3 in diagnosing UC was 50% whereas the specificity was 100%. GATA3 and uroplakin 3 showed statistically significant inverse relation with lymphovascular and muscle invasion.
CONCLUSION: GATA3 is more sensitive than uroplakin 3 for UC that can be effectively used to exclude PAC and CRC. Moreover, GATA3 and uroplakin 3 expression significantly decreases with lymphovascular invasion as well as muscle proper invasion which emphasizes their good prognostic role.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Witjes A, Max Bruins H, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur Urol. 2021;79(1):82-4. https://doi.org/10.1016/j.eururo.2020.03.055 Mid:32360052 DOI: https://doi.org/10.1016/j.eururo.2020.03.055
Oh WJ, Chung AM, Kim JS, Han JH, Hong SH, Lee JY, et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma. J Pathol Transl Med. 2016;50(5):345-4. https://doi.org/10.4132/jptm.2016.06.14 PMid:27498545 DOI: https://doi.org/10.4132/jptm.2016.06.14
Kerith O, Parviz H. Urothelial and prostate carcinoma metastasizing to the same lymph node: A case report and review of the literature. Arch Pathol Lab Med. 2001;125(10):1354-7. DOI: https://doi.org/10.5858/2001-125-1354-UAPCMT
Chen JC, Ho CL, Tsai HW, Tzai TS, Liu HS, Chow NH, et al. Immunohistochemical detection of prostate-specific antigen expression in primary urothelial carcinoma of the urinary bladder. Anticancer Res. 2008;28(6B):4149-4. Mid:19192675
Kondo A, Sasaki T, Kitaguchi D, Tsukada Y, Nishizawa Y, Ito M, et al. Resection of the urinary bladder for locally advanced colorectal cancer: A retrospective comparison of partial versus total cystectomy. BMC Surg. 2019;19(1):63. https://doi.org/10.1186/s12893-019-0522-8 PMid:31208384 DOI: https://doi.org/10.1186/s12893-019-0522-8
Yudai O, Hinata N, Murakami G, Bando Y, Kitamura K, Hussein AA, et al. Aspects of lymphatic vessel configuration of the human male urinary bladder and adjacent organs: A histological basis for understanding the spread of cancer metastases. Transl Res Anat. 2018;11:10-7. DOI: https://doi.org/10.1016/j.tria.2018.05.001
Shinohara M, Shin T, Daa T, Mimata H. GATA‐3 expression in primary pure choriocarcinoma of the bladder. IJU Case Rep. 2020;3(2):76-8. https://doi.org/10.1002/iju5.12151 PMid:32743476 DOI: https://doi.org/10.1002/iju5.12151
Agarwal H, Babu S, Rana C, Kumar M, Singhai A, Shankhwar SN, et al. Diagnostic utility of Gata3 immunohistochemical expression in urothelial carcinoma. Indian J Pathol Microbiol. 2019;62:244. https://doi.org/10.4103/IJPM.IJPM_228_18 PMid:30971548 DOI: https://doi.org/10.4103/IJPM.IJPM_228_18
Kaufmann O, Volmerig J, Dietel M. Uroplakin 3 is a highly specific moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Path. 2000;113(5):683-7. https://doi.org/10.1309/PYQC-17CB-063T-Q07J PMid:10800401 DOI: https://doi.org/10.1309/PYQC-17CB-063T-Q07J
Chang A, Amin A, Gabrielson E. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012;36(10):1472-6. https://doi.org/10.1097/PAS.0b013e318260cde7 PMid:22982890 DOI: https://doi.org/10.1097/PAS.0b013e318260cde7
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, et al. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38(1):13-2. https://doi.org/10.1097/PAS.0b013e3182a0218f PMid:24145643 DOI: https://doi.org/10.1097/PAS.0b013e3182a0218f
Wang Y, Zhang J, Wang S, Wang S, Zhang Y, Miao Q, et al. Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma. Front Med. 2019;13(6):730-40. https://doi.org/10.1007/s11684-019-0687-7 PMid:31020542 DOI: https://doi.org/10.1007/s11684-019-0687-7
Inoue S, MizushimaT, Fujita K, Meliti A, Ide H, Yamaguchi S, et al. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. Hum Pathol. 2017;64:83. DOI: https://doi.org/10.1016/j.humpath.2017.04.003
Matsumoto K, Satoh T, Irie A, Ishii J, Kuwao S, Iwamura M, et al. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology. 2008;72(2):444-9. https://doi.org/10.1016/j.urology.2007.11.128 PMid:18313120 DOI: https://doi.org/10.1016/j.urology.2007.11.128
Naji A, Mahdi A, Kerbel H. The immunoreactivity of uroplakin III in urothelial carcinoma of urinary bladder and other non-urothelial carcinoma. Medico Legal Update. 2019;19(2):319-3. DOI: https://doi.org/10.5958/0974-1283.2019.00196.8
Downloads
Published
How to Cite
License
Copyright (c) 2022 Maha Salama, Dina A. Khairy (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
